Evidence map›Paper›PMID 22922937›Full record

ArticleOncology reports2012

Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.

Nicole A Doudican, Shih Ya Wen, Amitabha Mazumder, Seth J Orlow

Open access · bronzeAbstract read
In one paragraph

Article in Oncology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Molecular targets of isothiocyanates in cancer: recent advances.Molecular nutrition & food research · 2014
    Review
  14. Translational regulator eIF2α in tumor.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nicole A DoudicanThe Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY 10016 , USA.
Shih Ya Wen
Amitabha Mazumder
Seth J Orlow
New York University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persistent paraprotein production in plasma cells necessitates a highly developed rough endoplasmic reticulum (ER) that is unusually susceptible to perturbations in protein synthesis. This biology is believed to account for the exquisite sensitivity of multiple myeloma (MM) to the proteasomal inhibitor bortezomib (BTZ). Despite remarkable response rates to BTZ in MM, BTZ carries the potential for serious side-effects and development of resistance. We, therefore, sought to identify therapeutic combinations that effectively disrupt proteostasis in order to provide new potential treatments for MM. We found that sulforaphane, a dietary isothiocyanate found in cruciferous vegetables, inhibits TNFα-induced Iκβ proteasomal degradation in a manner similar to BTZ. Like BTZ, sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide (ATO), an agent with clinical activity in MM. ATO and sulforaphane co-treatment augmented apoptotic induction as demonstrated by cleavage of caspase-3, -4 and PARP. The enhanced apoptotic response was dependent upon production of reactive oxygen species (ROS) as demonstrated by glutathione depletion and partial inhibition of the apoptotic cascade after pretreatment with the radical scavenger N-acetyl-cysteine (NAC). Combination treatment resulted in enhanced ER stress signaling and activation of the unfolded protein response (UPR), indicative of perturbation of proteostasis. Specifically, combination treatment caused elevated expression of the molecular chaperone HSP90 (heat shock protein 90) along with increased PERK (protein kinase RNA-like endoplasmic reticulum kinase) and eIF2α phosphorylation and XBP1 (X-box binding protein 1) splicing, key indicators of UPR activation. Moreover, increased splicing of XBP1 was apparent upon combination treatment compared to treatment with either agent alone. Sulforaphane in combination with ATO effectively disrupts protein homeostasis through ROS generation and induction of ER stress to culminate in inhibition of protein secretion and apoptotic induction in MM. Our results suggest that sulforaphane deserves further investigation in combination with ATO in the treatment of MM.

Indexed as

Antineoplastic AgentsApoptosisArsenicalsArsenic TrioxideCaspase 3Caspases, InitiatorCell Line, TumorCell ProliferationDNA-Binding ProteinsDrug SynergismeIF-2 KinaseEndoplasmic ReticulumEndoplasmic Reticulum StressEukaryotic Initiation Factor-2GlutathioneHSP90 Heat-Shock ProteinsAntineoplastic AgentsArsenicalsArsenic TrioxideCASP4 protein, humanCaspase 3Caspases, InitiatorDNA-Binding ProteinseIF-2 KinaseEukaryotic Initiation Factor-2GlutathioneHSP90 Heat-Shock ProteinsI-kappa B KinaseIsothiocyanatesOxidesPoly(ADP-ribose) PolymerasesReactive Oxygen SpeciesRegulatory Factor X Transcription FactorssulforaphaneSulfoxidesThiocyanatesTranscription FactorsTumor Necrosis Factor-alphaX-Box Binding Protein 1XBP1 protein, human

Identifiers

PMID22922937
PMCPMC3981004
OpenAlexW2082435121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.